Sandbox/AL
< Sandbox
Diagnosis
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[1][2]
Abbreviations: BP: blood pressure; CXR: chest X-ray; ECG: electrocardiogram; LV: left ventricle
Characterize the symptoms: Acute ❑ Dyspnea on exertion ❑ Orthopnea ❑ Paroxysmal nocturnal dyspnea ❑ Palpitations ❑ Chest pain | |||||||||||||||||||||||||||||||||||||||
Inquire about past medical history: ❑ Previously healthy ❑ Cardiac disease: ❑ Rheumatic fever ❑ Pulmonary disease | |||||||||||||||||||||||||||||||||||||||
Examine the patient: Vitals
Cardiovascular examination
❑ Search for other signs suggestive of aortic regurgitation
Respiratory examination | |||||||||||||||||||||||||||||||||||||||
Order imaging studies:
❑ ECG
❑ TTE (most important evaluation test) (Class I; Level of Evidence: B)
| |||||||||||||||||||||||||||||||||||||||
Acute ❑ ❑ | Chronic ❑ ❑ | ||||||||||||||||||||||||||||||||||||||
Interpret the results from TTE
Risk of AI (Stage A) ❑ No regurgitation Mild (Stage B) ❑ Vena contracta <0.3 cm ❑ Jet/LVOT <25% ❑ Regurgitant volume <30 mL/beat ❑ Regurgitant fraction <30% ❑ Effective regurgitant orifice <0.10 cm² Moderate (Stage B) ❑ Vena contracta 0.3-0.6 cm ❑ Jet/LVOT 25-64% ❑ Regurgitant volume 30-59 mL/beat ❑ Regurgitant fraction 30-49% ❑ Effective regurgitant orifice 0.10-0.29 cm² Severe ❑ Vena contracta >0.6 cm ❑ Jet/LVOT ≥ 65% ❑ Regurgitant volume ≥60 mL/beat ❑ Regurgitant fraction ≥50% ❑ Effective regurgitant orifice ≥ 0.30 cm² ❑ Holodiastolic flow reversal in the proximal abdominal aorta | |||||||||||||||||||||||||||||||||||||||
Asymptomatic (Stage C) | Symptomatic (Stage D) | ||||||||||||||||||||||||||||||||||||||
Stage | TTE findings |
---|---|
A | ❑ No regurgitation |
B | Mild ❑ Vena contracta <0.3 cm ❑ Jet/LVOT <25% ❑ Regurgitant volume <30 mL/beat ❑ Regurgitant fraction <30% ❑ Effective regurgitant orifice <0.10 cm² Moderate (Stage B) |
C1 | cell |
C2 | cell |
D | cell |
- ↑ Nishimura, R. A.; Otto, C. M.; Bonow, R. O.; Carabello, B. A.; Erwin, J. P.; Guyton, R. A.; O'Gara, P. T.; Ruiz, C. E.; Skubas, N. J.; Sorajja, P.; Sundt, T. M.; Thomas, J. D. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000031. ISSN 0009-7322.
- ↑ Bonow, R. O.; Carabello, B. A.; Chatterjee, K.; de Leon, A. C.; Faxon, D. P.; Freed, M. D.; Gaasch, W. H.; Lytle, B. W.; Nishimura, R. A.; O'Gara, P. T.; O'Rourke, R. A.; Otto, C. M.; Shah, P. M.; Shanewise, J. S. (2008). "2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–e661. doi:10.1161/CIRCULATIONAHA.108.190748. ISSN 0009-7322.
- ↑ Williams BR, Steinberg JP (2006). "Images in clinical medicine. Müller's sign". The New England Journal of Medicine. 355 (3): e3. doi:10.1056/NEJMicm050642. PMID 16855259. Retrieved 2012-04-15. Unknown parameter
|month=
ignored (help)